ArticleAnnals of surgical oncology2025
Endoscopic Transoropharyngeal Retropharyngeal Lymph Node (RPLN) Dissection for RPLN Recurrence Nasopharyngeal Carcinoma.
Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Toward Precision Chemotherapy in Colorectal Liver Metastases: Integrating Genomics into Predictive Modeling.Annals of surgical oncology · 2025Article
- ASO Author Reflections: Does More Lymphocyte Infiltration Indicate a Better Prognosis in Malignant Peritoneal Mesothelioma?Annals of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundRetropharyngeal lymph node (RPLN) dissection is difficult and lacks an ideal approach. We aimed to examine the efficacy of endoscopic transoropharyngeal RPLN dissection for patients with nasopharyngeal carcinoma (NPC) with RPLN recurrence. PATIENTS AND
methodsFrom January 2022 to July 2023, 25 patients with RPLN recurrence NPC were enrolled in the study. Clinical characteristics, complications, and survival outcomes were retrospectively analyzed.
resultsThe average surgical time and blood loss were 215±107 min (range 100-470 min) and 27.8 ± 18.4 mL (range 2-80 mL). With a median follow-up time of 20 months (95% CI 15.3-24.7), the 2-year overall survival, locoregional relapse-free survival, RPLN relapse-free survival, distant metastasis-free survival, and progression-free survival were 91.5%, 91.7%, 100%, 90.9%, and 83.3%, respectively. Only three patients suffered mild (grade 1) long-term morbidities.
conclusionsEndoscopic transoropharyngeal RPLN dissection was minimally invasive and demonstrated satisfactory tumor control with acceptable morbidities in treating patients with RPLN recurrence of NPC.
Indexed as
Identifiers
40588624What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.